MYGN
Myriad Genetics, Inc.

2,110
Mkt Cap
$600.3M
Volume
333,622.00
52W High
$16.83
52W Low
$3.76
PE Ratio
-1.49
MYGN Fundamentals
Price
$7.07
Prev Close
$6.44
Open
$6.55
50D MA
$7.47
Beta
1.21
Avg. Volume
922,881.96
EPS (Annual)
-$1.41
P/B
1.61
Rev/Employee
$310,222.22
Loading...
Loading...
News
all
press releases
How Did Tempus AI Power Its Move to Positive EBITDA in Q3?
TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Grows Position in Myriad Genetics, Inc. $MYGN
Connor Clark & Lunn Investment Management Ltd. raised its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 50.5% in the second quarter, according to the company in its most recent...
MarketBeat·6d ago
News Placeholder
Myriad Genetics (NASDAQ:MYGN) Given New $8.50 Price Target at Piper Sandler
Piper Sandler decreased their price target on shares of Myriad Genetics from $9.00 to $8.50 and set an "overweight" rating for the company in a report on Tuesday...
MarketBeat·8d ago
News Placeholder
Myriad Genetics (NASDAQ:MYGN) Price Target Raised to $6.50
Wells Fargo & Company lifted their target price on Myriad Genetics from $6.00 to $6.50 and gave the stock an "equal weight" rating in a report on Wednesday...
MarketBeat·14d ago
News Placeholder
Myriad (MYGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Myriad (MYGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·17d ago
News Placeholder
Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3
Myriad (MYGN) delivered earnings and revenue surprises of +100.00% and +0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation
HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.
Zacks·1mo ago
News Placeholder
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
Zacks·2mo ago
News Placeholder
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
Zacks·2mo ago
News Placeholder
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Myriad Genetics' Precise MRD study in The Lancet shows ctDNA detection power in oligometastatic ccRCC, supporting oncology growth plans.
Zacks·2mo ago

Latest MYGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.